Distinctive glycosylation signature and galectin-1 expression in different human breast cancer cell lines (BCC) and tissues

PERROTTA, RAMIRO; DALOTTO MORENO, TOMÁS; MOSES, FLORENCIA; CAGNONI, ALEJANDRO J.; MARIÑO, KARINA V.; CROCI, DIEGO O.; RABINOVICH, GABRIEL A.; SALATINO, MARIANA

Mar del Plata

Congreso; LXIV Reunión Anual de la Sociedad Argentina de Inmunología; 2016

Sociedad Argentina de Inmunología

Galectins can influence antitumor immune response, angiogenesis and tumor metastasis by interacting with cell surface glycans. Changes in glycosylation observed in malignant cells are specifically sensed by lectins and can be used as disease biomarkers. With the main goal of investigating the relevance of galectin-glycan interactions in shaping distinct breast cancer phenotypes, we first selected five human cell lines that model different human breast cancer types. To identify specific glycan structures, we used a panel of biotinylated lectins (Galectin-1 (Gal1), LEL, SNA, PNA, PHA-L and MAA) and analyzed their binding to the cell surface by flow cytometry. We found that highly aggressive lines, as the triple negative MDA-MB-231 and the HER2-enriched Trastuzumab (TZ)-resistant JIMT-1, showed higher binding of Gal1 (p